<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8645591</article-id><article-id pub-id-type="pmc">2074481</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pronzato</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bertelli</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vigani</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vaira</surname><given-names>F.</given-names></name></contrib></contrib-group><aff>U.O. Oncologia Medica, Ospedale S. Andrea, La Spezia, Italy.</aff><pub-date pub-type="ppub"><month>6</month><year>1996</year></pub-date><volume>73</volume><issue>11</issue><fpage>1425</fpage><lpage>1427</lpage><abstract><p>We have evaluated the feasibility of an increase in dose intensity of the cisplatin, epidoxorubicin and cyclophosphamide (PEC) regimen, with granulocyte colony-stimulating factor (G-CSF) support, in 22 patients with advanced ovarian cancer. Twenty-one patients (95.4%) received six cycles of treatment: of these, 13 (61.9%) were also able to repeat cycles every 14 days as planned. Marrow toxicity was similar to that observed during conventional treatments. No severe mucositis or thrombocytopenia was observed. A clinical complete response was observed in 9 out of 16 evaluable patients (56.2%).</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00039-0117.tif" xlink:title="scanned-page" xlink:role="1425" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00039-0118.tif" xlink:title="scanned-page" xlink:role="1426" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00039-0119.tif" xlink:title="scanned-page" xlink:role="1427" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

